This is a quote from Dr Andtbacker from 2 years ago. We have great results as per the quote but half the valuation from the board. What changed?
"I'd like to see some action on the Keytruda/CVA21 combo. Fortunately, in two weeks we should see some good news at ASCO, finally, on the results of the Yervoy/CVA combo trials that began early last year. Yervoy is a Bristol Myers immuno-therapy that is being superseded by its own Optivo with annual sales of one billion dollars. Would be very nice to see Cavatak provide major improvements as a combo drug with any of Yervoy, Optivo and Keytruda. Then a billion dollar valuation for VLA ($4 plus per share) won't look silly."
- Forums
- ASX - By Stock
- Incredulous
This is a quote from Dr Andtbacker from 2 years ago. We have...
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online